JMT101 and osimertinib vs chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted drug (JMT101) combined with another targeted therapy (osimertinib) versus standard chemotherapy for people with a specific type of advanced lung cancer. It is for those whose tumors have an EGFR exon 20 insertion mutation and who have not received prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your lung cancer is advanced or has spread (stage IIIB, IIIC, or IV) and cannot be cured with current treatments.
- Your tumor has a specific change in the EGFR gene called an exon 20 insertion mutation (confirmed by a blood or tissue test).
- You have at least one tumor that can be measured by scans (like CT or MRI).
- You have not had any previous cancer treatment for your advanced or metastatic lung cancer.
- You do not have brain metastases that are causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
This trial tests a combination of a targeted therapy (JMT101) with chemotherapy for a type of lung cancer called squamous cell non-small cell lung cancer that has a specific marker (EGFR). It is for patients whose cancer has gotten worse after prior immunotherapy and chemotherapy.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Local Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.